Melanoma-prone families : new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers
Germline mutations on the CDKN2A gene, the most important known genetic factors associated with cutaneous melanomas (CMs), predispose carriers to multiple primary CMs (MPMs) with higher frequency and younger onset compared to non-carriers. Most of the largest published studies concerning clinical and histological characteristics of CMs with CDKN2A mutation carriers did not specify if the described CMs are first or subsequent to the first, and they used sporadic CMs from non-genotyped patients as controls. We conducted a single-centre observational study to compare clinical and histological CM features of 32 unrelated carriers (MUT) of 5 germline CDKN2A mutations (one of which was never previously described) compared to 100 genotyped wild-type (WT) patients. We stratified the data based on time of diagnosis, anatomical site and histological subtype of CMs, demonstrating several significant unreported differences between the two groups. MUT developed a higher number of dysplastic nevi and MPMs. We proved for the first time that anatomical distribution of CMs in MUT was independent of gender, unlike WTs. MUTs developed in situ and superficial spreading melanomas (SSMs) more frequently, with significantly higher number of SSMs on the head/neck. In MUTs, Breslow thickness was significantly lower for all invasive CMs. When CMs were stratified on the basis of the time of occurrence, statistical significance was maintained only for SSMs subsequent to the first. In WTs, Clark level was significantly higher, and ulceration was more prevalent than in MUTs. Significant differences in ulceration were observed only in SSMs. In nodular CMs, we did not find differences in terms of Breslow thickness or ulceration between WTs and MUTs. In situ CMs developed 10 years earlier in MUTs with respect to WTs, whereas no significant differences were observed in invasive CMs. In contrast to those reported previously by other authors, we did not find a difference in skin phototype.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:310 |
|---|---|
| Enthalten in: |
Archives of dermatological research - 310(2018), 10 vom: 14. Dez., Seite 769-784 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gironi, Laura Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.06.2019 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00403-018-1866-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288550234 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288550234 | ||
| 003 | DE-627 | ||
| 005 | 20231225060550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00403-018-1866-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0961.xml |
| 035 | |a (DE-627)NLM288550234 | ||
| 035 | |a (NLM)30218143 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gironi, Laura Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Melanoma-prone families |b new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.06.2019 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Germline mutations on the CDKN2A gene, the most important known genetic factors associated with cutaneous melanomas (CMs), predispose carriers to multiple primary CMs (MPMs) with higher frequency and younger onset compared to non-carriers. Most of the largest published studies concerning clinical and histological characteristics of CMs with CDKN2A mutation carriers did not specify if the described CMs are first or subsequent to the first, and they used sporadic CMs from non-genotyped patients as controls. We conducted a single-centre observational study to compare clinical and histological CM features of 32 unrelated carriers (MUT) of 5 germline CDKN2A mutations (one of which was never previously described) compared to 100 genotyped wild-type (WT) patients. We stratified the data based on time of diagnosis, anatomical site and histological subtype of CMs, demonstrating several significant unreported differences between the two groups. MUT developed a higher number of dysplastic nevi and MPMs. We proved for the first time that anatomical distribution of CMs in MUT was independent of gender, unlike WTs. MUTs developed in situ and superficial spreading melanomas (SSMs) more frequently, with significantly higher number of SSMs on the head/neck. In MUTs, Breslow thickness was significantly lower for all invasive CMs. When CMs were stratified on the basis of the time of occurrence, statistical significance was maintained only for SSMs subsequent to the first. In WTs, Clark level was significantly higher, and ulceration was more prevalent than in MUTs. Significant differences in ulceration were observed only in SSMs. In nodular CMs, we did not find differences in terms of Breslow thickness or ulceration between WTs and MUTs. In situ CMs developed 10 years earlier in MUTs with respect to WTs, whereas no significant differences were observed in invasive CMs. In contrast to those reported previously by other authors, we did not find a difference in skin phototype | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a CDKN2A | |
| 650 | 4 | |a Cutaneous melanoma | |
| 650 | 4 | |a Familial melanoma | |
| 650 | 4 | |a Melanoma-susceptibility genes | |
| 650 | 4 | |a Risk factor for cutaneous melanoma | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a CDKN2A protein, human |2 NLM | |
| 650 | 7 | |a Cyclin-Dependent Kinase Inhibitor p16 |2 NLM | |
| 700 | 1 | |a Colombo, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Pasini, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgione, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Farinelli, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Zottarelli, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Esposto, Elia |e verfasserin |4 aut | |
| 700 | 1 | |a Zavattaro, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Allara, Elias |e verfasserin |4 aut | |
| 700 | 1 | |a Ogliara, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Betti, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Dianzani, Irma |e verfasserin |4 aut | |
| 700 | 1 | |a Savoia, Paola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of dermatological research |d 1986 |g 310(2018), 10 vom: 14. Dez., Seite 769-784 |w (DE-627)NLM00029716X |x 1432-069X |7 nnns |
| 773 | 1 | 8 | |g volume:310 |g year:2018 |g number:10 |g day:14 |g month:12 |g pages:769-784 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00403-018-1866-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 310 |j 2018 |e 10 |b 14 |c 12 |h 769-784 | ||